{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06264921",
            "orgStudyIdInfo": {
                "id": "NKT3447-101"
            },
            "organization": {
                "fullName": "NiKang Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors",
            "officialTitle": "A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-with-for-adults-with-advanced-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-09",
            "studyFirstSubmitQcDate": "2024-02-09",
            "studyFirstPostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NiKang Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).",
            "detailedDescription": "This is a Phase 1/1b, first-in-human, open-label, multicenter study of NKT3447 in adults with advanced/ metastatic solid tumors. The study consists of 2 parts, a Dose Escalation phase and a Dose Expansion phase. Eligible patients must have confirmed advanced/metastatic solid tumors (as outlined below) with disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment likely to improve the disease outcome in the judgment of the investigator.\n\nDose Escalation:\n\n1. Ovarian cancer\n2. Endometrial cancer\n3. Gastric cancer or gastroesophageal junction cancer\n4. Small cell lung cancer\n5. Triple-negative breast cancer (human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor negative)\n6. Estrogen receptor/progesterone-receptor + human epidermal growth factor receptor 2 negative (HER2-) breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and not suitable for endocrine therapy)\n7. Other solid tumors with CCNE1 amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next generation sequencing by local liquid or tissue biopsy.\n\nDose Expansion:\n\na. Platinum resistant or refractory ovarian cancer (defined as recurrence \u22646 months after completing platinum-based regimen) with progression on at least 1 platinum containing therapy with cyclin E amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next-generation sequencing by local liquid or tissue biopsy.\n\nThe Dose Escalation phase will evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors.\n\nThe Dose Expansion phase will evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with CCNE1 amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended RP2D."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor",
                "Solid Tumor, Adult",
                "Advanced Solid Tumor",
                "Metastatic Tumor",
                "Ovarian Cancer",
                "Ovarian Neoplasms",
                "Ovarian Carcinoma",
                "Metastatic Ovarian Carcinoma",
                "Endometrial Cancer",
                "Endometrial Neoplasms",
                "Endometrial Diseases",
                "Metastatic Endometrial Cancer",
                "Metastatic Endometrial Carcinoma",
                "Advanced Endometrial Carcinoma",
                "Advanced Ovarian Carcinoma",
                "Gastric Cancer",
                "Advanced Gastric Carcinoma",
                "Metastatic Gastric Cancer",
                "Metastatic Gastric Carcinoma",
                "Small-cell Lung Cancer",
                "Small Cell Lung Carcinoma",
                "Triple Negative Breast Cancer",
                "Triple Negative Breast Neoplasms",
                "Platinum-resistant Ovarian Cancer",
                "Platinum-refractory Ovarian Carcinoma",
                "CCNE1 Amplification",
                "Hormone Receptor Negative Breast Carcinoma",
                "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
                "Progesterone-receptor-positive Breast Cancer"
            ],
            "keywords": [
                "CDK 2 Inhibitor",
                "CDK 4 Inhibitor",
                "CDK 6 Inhibitor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Dose Escalation and Dose Expansion",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Randomized for the Expansion Phase"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3447 at increasing dosage levels to determine the MTD and/or preliminary RDEs.",
                    "interventionNames": [
                        "Drug: NKT3447"
                    ]
                },
                {
                    "label": "Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Dose expansion will include 2 RDEs selected to determine the preliminary antitumor activity and the RP2D.",
                    "interventionNames": [
                        "Drug: NKT3447"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NKT3447",
                    "description": "Oral CDK2 inhibitor",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Dose Limiting Toxicity (DLT) events",
                    "description": "DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0.",
                    "timeFrame": "28 days"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as determined by the Investigator",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Disease control rate",
                    "description": "Disease control rate defined as CR + PR + stable disease \\[SD\\]",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS defined as the time from the date the participant started study drug to death for any reason.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Number of Participants with Adverse Events",
                    "description": "An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax) of NKT3447",
                    "description": "Maximum observed plasma concentration (Cmax) of NKT3447",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Time to maximum observed plasma concentration of NKT3447 (Tmax)",
                    "description": "Time to maximum observed plasma concentration of NKT3447 (Tmax)",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Observed trough concentration of NKT3447 (Ctrough)",
                    "description": "Observed trough concentration of NKT3447 (Ctrough)",
                    "timeFrame": "88 weeks"
                },
                {
                    "measure": "Area under the plasma concentration-time curve (AUC0-t) of NKT3447",
                    "description": "Area under the plasma concentration-time curve (AUC0-t) of NKT3447",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Apparent clearance (CL/F)",
                    "description": "Apparent clearance (CL/F)",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Apparent volume of distribution (V/F)",
                    "description": "Apparent volume of distribution (V/F)",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Half-life (t1/2)",
                    "description": "Half-life (t1/2)",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Accumulation ratio (AR)",
                    "description": "Accumulation ratio (AR)",
                    "timeFrame": "1 month"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have confirmed unresectable advanced/metastatic solid tumors (as outlined below) with disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment likely to improve the disease outcome in the judgment of the investigator.\n\nDose Escalation:\n\n1. Ovarian cancer\n2. Endometrial cancer\n3. Gastric cancer or gastroesophageal junction cancer\n4. Small cell lung cancer\n5. Triple-negative breast cancer (human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor negative)\n6. Estrogen receptor/progesterone-receptor + human epidermal growth factor receptor 2 negative (HER2-) breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and not suitable for endocrine therapy)\n7. Other solid tumors with CCNE1 amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next generation sequencing by local liquid or tissue biopsy.\n\nDose Expansion:\n\na. Platinum resistant or refractory ovarian cancer (defined as recurrence \u22646 months after completing platinum-based regimen) with progression on at least 1 platinum containing therapy with cyclin E amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next-generation sequencing by local liquid or tissue biopsy.\n\n* Measurable disease per the RECIST v1.1\n* An Eastern Cooperative Oncology Group performance status of 0 to 1\n* Able to swallow oral medications.\n\nExclusion Criteria:\n\n* Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and/or radiotherapy, or chemotherapy.\n* History of another malignancy with exceptions\n* Visceral crisis, lymphangitic spread, CNS metastasis and/or carcinomatous meningitis\n* Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade \u2264 1 severity (per CTCAE)\n* Clinically active interstitial lung disease\n* History of uveitis, retinopathy or other clinically significant retinal disease\n* Has known human immunodeficiency virus (HIV), active hepatitis B or C infection\n* Prior CDK2 inhibitor, WEE1 inhibitor, or protein kinase membrane associated tyrosine/threonine 1 inhibitor.\n* Major surgery within 2 months or minor surgery within 10 days before the first dose of NKT3447",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sponsor Contact",
                    "role": "CONTACT",
                    "phone": "3024155127",
                    "email": "clinicaltrials@nikangtx.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kristy Tjokro",
                            "role": "CONTACT",
                            "email": "Kristy.Tjokro@ucsf.edu"
                        },
                        {
                            "name": "Edwin Alvarez, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute at HealthONE",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelly Mozzetta",
                            "role": "CONTACT",
                            "phone": "720-754-2610",
                            "email": "CANN.DDUDenverGeneral@SarahCannon.com"
                        },
                        {
                            "name": "Gerald Falchook, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "AdventHealth Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Celebration",
                    "state": "Florida",
                    "zip": "34747",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Osorio",
                            "role": "CONTACT",
                            "email": "Heather.Osorio@AdventHealth.com"
                        },
                        {
                            "name": "Karolina Kilowski, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.32529,
                        "lon": -81.53313
                    }
                },
                {
                    "facility": "Norton Cancer Institute - Broadway",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jade Alexander",
                            "role": "CONTACT",
                            "email": "jade.alexander@nortonhealthcare.org"
                        },
                        {
                            "role": "CONTACT",
                            "email": "EarlyPhase-NCIResearch@nortonhealthcare.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "The Gabrail Pharmacology Phase 1 Research Center",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carrie Smith",
                            "role": "CONTACT",
                            "email": "csmith@gabrailcancercenter.com"
                        },
                        {
                            "name": "Nashat Y Gabrail, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "Texas Oncology-Austin Midtown NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erica Torres",
                            "role": "CONTACT",
                            "phone": "210-610-5205",
                            "email": "etorres@nextoncology.com"
                        },
                        {
                            "name": "Andrae Vandross, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "START Mountain Region",
                    "status": "RECRUITING",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marie Asay",
                            "role": "CONTACT",
                            "phone": "801-907-4770",
                            "email": "marie.asay@startthecure.com"
                        },
                        {
                            "name": "Justin A Call, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "IPD are not planned to be shared at this time"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000077216",
                    "term": "Carcinoma, Ovarian Epithelial"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                },
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                },
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Small Cell Lung Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Tumors",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "asFound": "Ovarian Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "asFound": "Endometrial Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "asFound": "Gastric Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "asFound": "Ovarian Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}